Safety Escalating Repeat IV, in Stroke Patients "MAG111539"
Completed
Phase 2 ResultsSummary of Purpose
The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 17 October 2017.
8 Jul 2009 | 29 Jan 2009 | 31 Jan 2011 | 31 Jan 2011 | 1 Sep 2017 | 31 Jul 2017 |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Single Blind (Subject)
- Endpoint: Safety Study
- Intervention: Parallel Assignment
Contacts
-
Lori Enney anti-MAG CMT Leader Stroke & ALS Clinical Development Neurosciences MDC MAI-C.3640.3A; RTP Tel) 919-483-1420 Fax) 919-483-6763 Cell) 919-423-2977 e-mail) Lori.A.Enney@gsk.com
Lori.A.Enney@gsk.com
View Trial Locations
Recruitment
- Enrollment: 42
- Gender: All
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 16 locations, 3 countries
Principal Investigator
- GSK Clinical Trials
GlaxoSmithKline